Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPT001-HTY neoantigen-pulsed dendritic cell therapy in unresectable esophageal squamous cell carcinoma
jRCT2033240683Phase 1Not yet recruiting
- Sponsor
- Neuropore Therapies, Inc.
- Start
- Feb 2025
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NPT001-HTY in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Neuropore Therapies, Inc. Primary endpoints: Dose-limiting toxicity (DLT), Maximum tolerated dose (MTD) and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
NPT001-HTY
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2033240683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240683.